Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(1.56) by 72.44 percent. This is a 80.09 percent increase over losses of $(2.16) per share from the same period last year.